Table 1.

Association of baseline VEGF with clinical response at week 24 for 157 patients treated with ipilimumab

Response# Patients status at week 24 (%)# Patients (VEGF < 43 pg/mL)# Patients (VEGF ≥ 43 pg/mL)
Complete response321
Partial response1385
Stable disease372710
Clinical benefit53 (33%)37 (41.1%)16 (23.2%)
Progressive disease543024
Disease of death522329
No clinical benefit106 (67%)53 (58.9%)53 (76.8%)
Total1599069

NOTE: Fisher exact t test; P = 0.019.